Asset
Neldaleucel
Marker Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05798897 | phase1 | recruiting | 2023-01-02 | 2028-02-28 | Marker Therapeutics, Inc. | Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma |
FDA applications (0)
This company has no applications containing this asset.